L-NAME has a 72% probability of crossing the blood–brain barrier [46], making it conceivable that cognitive decline following L-NAME treatment is merely due to the inhibition of nNOS in the brain, independent of arterial stiffening. This evidence concerns the gene NOS1 and Mental deterioration.